. 11. Giantonio BJ Catalano PJ Meropol NJ . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
Search Results
In Defense of Hepatic Arterial Infusion for Hepatic Metastases of Colorectal Cancer
Nancy Kemeny
NCCN Guidelines® Updates: Kidney Cancer
Certain Circumstances: ∘ “Bevacizumab .... and renal cell cancer carcinoma (HLRCC)- associated RCC ” was revised.
QIM20-124: Retrospective Evaluation of VEGF Inhibitor-Associated Hypertension at a Community Cancer Center
Jasmin Eugene, Carli Nesheiwat, and Scott Overmier
retrospective, single-center, chart review assessed patients’ blood pressure measurements who received bevacizumab, ramucirumab, sorafenib, regorafenib, sunitinib, or pazopanib. Patients were excluded if they were less than 18, received VEGF inhibitors for non
QIM22-203: Randomized Trial of Implementing a Clinical Decision Support Tool for Automatic Selection of Payor-Mandated Biosimilar at Time of Prescribing
Shayna Simon, Lindsey Skelton, Sherry F. Parker, Rebecca Brian, Waddah Arafat, and Muhammad Shaalan Beg
tool is being validated for two additional oncology reference products (bevacizumab, trastuzumab). EMR based tools can help manage the complexity of ordering biosimilars in the current healthcare system.
BPI20-012: Relative Risk of Various Endocrinopathies Associated With the Use of Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Renal Cell Carcinoma: a Systematic Review and Meta-Analysis
Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Somedeb Ball, Fred Hardwicke, Lukman Tijani, and Shabnam Rehman
. For hypophysitis and diabetes, CheckMate 214 and KEYNOTE-426 including 1936 patients were analyzed. ICI regimens used in the study arms are — CheckMate 214: nivolumab + ipilimumab; IMmotion151: atezolizumab + bevacizumab; JAVELIN Renal 101: axitinib
QIM22-198: Optimizing a Systemic Platform to Standardize Oncologic Biosimilars Utilization at Cedars-Sinai Medical Center (CSMC)
Suwicha Limvorasak, Hilary Teaford, Crystal Leung Dobbs, Kyung Kim, Marcio A. Diniz, Andre Rogatko, Edwin M. Posadas, Kevin S. Scher, Vipul Patel, Bruce Vinson, Leanne Sakamoto, Rita Shane, Robert A. Figlin, and Karen L. Reckamp
substitution within the electronic order set. For this interim report, we identified adult cancer patients who initiated treatment with bevacizumab, rituximab or trastuzumab between January to October 2021 through electronic health record. Conversion rate was
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer
Sushmita Gordhandas, William A. Zammarrelli III, Eric V. Rios-Doria, Angela K. Green, and Vicky Makker
. Following frontline TC, the benefit of subsequent chemotherapy is modest, with a median PFS of 3 to 4 months and OS of 6 to 12 months. 1 The anti-VEGF antibody bevacizumab is also active in advanced EC as monotherapy and has been explored in combination
Colon Cancer
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
metastatic colorectal cancer treated with cetuximab . Ann Oncol 2008 ; 19 : 508 – 515 . 28 Punt CJ Tol J Rodenburg CJ . Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal
Challenges in the Management of Older Patients With Colon Cancer
Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger
metastatic colon cancer. The Use of Biologic Agents in the Older Population Bevacizumab The addition of the vascular endothelial growth factor antibody bevacizumab has been shown to improve progression-free and overall survivals among patients
Value-Based Insurance Design: Aligning Incentives, Benefits, and Evidence in Oncology
Jonas A. de Souza, Mark J. Ratain, and A. Mark Fendrick
, bevacizumab is the same price per milligram for patients with metastatic colorectal cancer (5 mg/kg every 2 weeks), in whom it provides a median overall survival benefit of 4.7 months 16 (hazard ratio [HR] for death, 0.66; 95% CI, 0.54-0.81; P < .001), as